-

Company Profile for bioAffinity Technologies, Inc.

--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology are conducted in bioAffinity Technologies’ laboratories at the University of Texas San Antonio (UTSA). The Company’s platform technology is being developed to diagnose, monitor and treat many cancers.

Company:

bioAffinity Technologies, Inc.

 

 

Headquarters Address:

22211 W I-10, Suite 1206

 

San Antonio, TX 78257

 

 

Main Telephone:

5054009747

 

 

Website:

www.bioaffinitytech.com

 

 

Type of Organization:

Private

 

 

Industry:

Biotechnology

 

 

Key Executives:

CEO: Maria Zannes

 

 

Public Relations

 

Contact:

Julie Anne Overton

Phone:

5055770918

Email:

jaoverton@mac.com

 

bioAffinity Technologies, Inc.

NASDAQ:BIAF
Details
Headquarters: San Antonio, TX
CEO: Maria Zannes
Employees: 52
Organization: PUB

Release Versions

More News From bioAffinity Technologies, Inc.

bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies will share benefits of CyPath Lung with North Carolina lung cancer patient advocacy and healthcare community at Nov. 5 event....

bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026

SAN ANTONIO, Texas--(BUSINESS WIRE)--bioAffinity Technologies sponsors Learning Theater at CHEST 2026 on clinical use of CyPath Lung for detection of lung cancer....

bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies to present positive data on new test under development to measure lung inflammation in asthma and COPD at CHEST 2026...
Back to Newsroom